Literature DB >> 10517956

Epidural resiniferatoxin induced prolonged regional analgesia to pain.

T Szabo1, Z Olah, M J Iadarola, P M Blumberg.   

Abstract

Adequate treatment of cancer pain remains a significant clinical problem. To reduce side effects of treatment, intrathecal and epidural routes of administration have been used where appropriate to reduce the total dose of agent administered while achieving regional control. Resiniferatoxin (RTX), an ultrapotent capsaicin analog, gives long-term desensitization of nociception via C-fiber sensory neurons. We evaluate here the analgesic effect on rats of epidurally administered RTX, using latency of response to a thermal stimulus in unrestrained animals. Results were compared with those for systemically administered RTX. Vehicle or graded doses of RTX were injected subcutaneously (s.c.) or through an indwelling lumbar (L4) epidural catheter as a single dose. Both routes of application of RTX produced profound thermal analgesia, reaching a plateau within 4-6 h and showing no restoration of pain sensitivity over 7 days. Vehicle was without effect. For the epidural route, the effect was selective as expected for the targeted spinal cord region, whereas the subcutaneous administration of RTX had a generalized analgesic effect. At doses yielding a tripling of back paw withdrawal latency, epidural treatment was 25-fold more effective than the subcutaneous route of application. Consistent with the regional selectivity of the lumbar epidural route, the front paws showed no more effect than by systemic RTX treatment. Binding experiments with [3H]RTX provided further evidence of the segmental desensitization induced by epidural RTX. We conclude that epidural administration of RTX at the lumbar spinal level produces profound, long-lasting, segmental analgesia to C-fiber mediated pain in the rat.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10517956     DOI: 10.1016/s0006-8993(99)01763-1

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  12 in total

Review 1.  Intrathecal drug delivery for chronic pain management-scope, limitations and future.

Authors:  M Czernicki; G Sinovich; I Mihaylov; B Nejad; S Kunnumpurath; G Kodumudi; N Vadivelu
Journal:  J Clin Monit Comput       Date:  2014-08-31       Impact factor: 2.502

2.  Preservation of acute pain and efferent functions following intrathecal resiniferatoxin-induced analgesia in rats.

Authors:  Mahendra Bishnoi; Christine A Bosgraaf; Louis S Premkumar
Journal:  J Pain       Date:  2011-06-16       Impact factor: 5.820

3.  Activation of transient receptor potential vanilloid 1 (TRPV1) by resiniferatoxin.

Authors:  Manish Raisinghani; Reddy M Pabbidi; Louis S Premkumar
Journal:  J Physiol       Date:  2005-07-21       Impact factor: 5.182

Review 4.  Current developments in intraspinal agents for cancer and noncancer pain.

Authors:  Erin F Lawson; Mark S Wallace
Journal:  Curr Pain Headache Rep       Date:  2010-02

Review 5.  The neurobiology of cancer pain.

Authors:  Brian L Schmidt
Journal:  Neuroscientist       Date:  2014-03-24       Impact factor: 7.519

6.  Resiniferatoxin (RTX) causes a uniquely protracted musculoskeletal hyperalgesia in mice by activation of TRPV1 receptors.

Authors:  Ramy E Abdelhamid; Katalin J Kovács; Christopher N Honda; Myra G Nunez; Alice A Larson
Journal:  J Pain       Date:  2013-11-01       Impact factor: 5.820

Review 7.  Use of Capsaicin to Treat Pain: Mechanistic and Therapeutic Considerations.

Authors:  Man-Kyo Chung; James N Campbell
Journal:  Pharmaceuticals (Basel)       Date:  2016-11-01

8.  TRPV1: a target for next generation analgesics.

Authors:  Louis S Premkumar; Parul Sikand
Journal:  Curr Neuropharmacol       Date:  2008-06       Impact factor: 7.363

9.  Selective targeting of TRPV1 expressing sensory nerve terminals in the spinal cord for long lasting analgesia.

Authors:  Joseph A Jeffry; Shuang-Quan Yu; Parul Sikand; Arti Parihar; M Steven Evans; Louis S Premkumar
Journal:  PLoS One       Date:  2009-09-15       Impact factor: 3.240

10.  Perineural resiniferatoxin selectively inhibits inflammatory hyperalgesia.

Authors:  John K Neubert; Andrew J Mannes; Laszlo J Karai; Alan C Jenkins; Lanel Zawatski; Mones Abu-Asab; Michael J Iadarola
Journal:  Mol Pain       Date:  2008-01-16       Impact factor: 3.395

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.